178 related articles for article (PubMed ID: 19267352)
21. A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer.
Fenoglio D; Traverso P; Parodi A; Tomasello L; Negrini S; Kalli F; Battaglia F; Ferrera F; Sciallero S; Murdaca G; Setti M; Sobrero A; Boccardo F; Cittadini G; Puppo F; Criscuolo D; Carmignani G; Indiveri F; Filaci G
Cancer Immunol Immunother; 2013 Jun; 62(6):1041-52. PubMed ID: 23591981
[TBL] [Abstract][Full Text] [Related]
22. Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697).
Lawson DH; Lee S; Zhao F; Tarhini AA; Margolin KA; Ernstoff MS; Atkins MB; Cohen GI; Whiteside TL; Butterfield LH; Kirkwood JM
J Clin Oncol; 2015 Dec; 33(34):4066-76. PubMed ID: 26351350
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
[TBL] [Abstract][Full Text] [Related]
24. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease.
Murphy GP; Tjoa BA; Simmons SJ; Jarisch J; Bowes VA; Ragde H; Rogers M; Elgamal A; Kenny GM; Cobb OE; Ireton RC; Troychak MJ; Salgaller ML; Boynton AL
Prostate; 1999 Jan; 38(1):73-8. PubMed ID: 9973112
[TBL] [Abstract][Full Text] [Related]
25. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer.
Rini BI; Weinberg V; Bok R; Small EJ
J Clin Oncol; 2003 Jan; 21(1):99-105. PubMed ID: 12506177
[TBL] [Abstract][Full Text] [Related]
27. Clinical safety of a viral vector based prostate cancer vaccine strategy.
Arlen PM; Skarupa L; Pazdur M; Seetharam M; Tsang KY; Grosenbach DW; Feldman J; Poole DJ; Litzinger M; Steinberg SM; Jones E; Chen C; Marte J; Parnes H; Wright J; Dahut W; Schlom J; Gulley JL
J Urol; 2007 Oct; 178(4 Pt 1):1515-20. PubMed ID: 17707059
[TBL] [Abstract][Full Text] [Related]
28. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
Weihrauch MR; Ansén S; Jurkiewicz E; Geisen C; Xia Z; Anderson KS; Gracien E; Schmidt M; Wittig B; Diehl V; Wolf J; Bohlen H; Nadler LM
Clin Cancer Res; 2005 Aug; 11(16):5993-6001. PubMed ID: 16115944
[TBL] [Abstract][Full Text] [Related]
29. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time.
Chudley L; McCann K; Mander A; Tjelle T; Campos-Perez J; Godeseth R; Creak A; Dobbyn J; Johnson B; Bass P; Heath C; Kerr P; Mathiesen I; Dearnaley D; Stevenson F; Ottensmeier C
Cancer Immunol Immunother; 2012 Nov; 61(11):2161-70. PubMed ID: 22729556
[TBL] [Abstract][Full Text] [Related]
30. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.
Kaufman HL; Wang W; Manola J; DiPaola RS; Ko YJ; Sweeney C; Whiteside TL; Schlom J; Wilding G; Weiner LM
J Clin Oncol; 2004 Jun; 22(11):2122-32. PubMed ID: 15169798
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B
J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769
[TBL] [Abstract][Full Text] [Related]
32. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer.
Noguchi M; Itoh K; Suekane S; Morinaga A; Sukehiro A; Suetsugu N; Katagiri K; Yamada A; Noda S
Prostate; 2004 Jun; 60(1):32-45. PubMed ID: 15129427
[TBL] [Abstract][Full Text] [Related]
33. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.
Sonpavde G; Aparicio AM; Zhan F; North B; Delaune R; Garbo LE; Rousey SR; Weinstein RE; Xiao L; Boehm KA; Asmar L; Fleming MT; Galsky MD; Berry WR; Von Hoff DD
Urol Oncol; 2011; 29(6):682-9. PubMed ID: 19959380
[TBL] [Abstract][Full Text] [Related]
34. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.
Dreicer R; Stadler WM; Ahmann FR; Whiteside T; Bizouarne N; Acres B; Limacher JM; Squiban P; Pantuck A
Invest New Drugs; 2009 Aug; 27(4):379-86. PubMed ID: 18931824
[TBL] [Abstract][Full Text] [Related]
35. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
Murray JL; Gillogly ME; Przepiorka D; Brewer H; Ibrahim NK; Booser DJ; Hortobagyi GN; Kudelka AP; Grabstein KH; Cheever MA; Ioannides CG
Clin Cancer Res; 2002 Nov; 8(11):3407-18. PubMed ID: 12429628
[TBL] [Abstract][Full Text] [Related]
36. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
[TBL] [Abstract][Full Text] [Related]
37. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
Knutson KL; Schiffman K; Cheever MA; Disis ML
Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.
Lechleider RJ; Arlen PM; Tsang KY; Steinberg SM; Yokokawa J; Cereda V; Camphausen K; Schlom J; Dahut WL; Gulley JL
Clin Cancer Res; 2008 Aug; 14(16):5284-91. PubMed ID: 18698048
[TBL] [Abstract][Full Text] [Related]
39. Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer.
McNeel DG; Eickhoff JC; Johnson LE; Roth AR; Perk TG; Fong L; Antonarakis ES; Wargowski E; Jeraj R; Liu G
J Clin Oncol; 2019 Dec; 37(36):3507-3517. PubMed ID: 31644357
[TBL] [Abstract][Full Text] [Related]
40. Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate.
Amato RJ; Hernandez-McClain J; Henary H
Urol Oncol; 2009; 27(1):8-13. PubMed ID: 18367123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
